IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

A Comprehensive Review on the Application of Artificial Intelligence in Pharmacovigilance

Seema Yadav, Priya Kumari, Ananya Anand, Shefali Singh, Dr. Anamika Verma, Shilpa Thakur

Jayoti Vidyapeeth Women's University, Jaipur, Rajasthan

Corresponding author:

Seema Yadav

Abstract: Pharmacovigilance has a critical role in promoting patient safety for both recently medications that have been introduced and those that are well-known brands. In the context of clinical trials, pharmaceutical operations are tightly regulated; nonetheless, post-marketing adverse event Reporting is not properly enforced or put into practice. As a result, it is estimated that 90% of adverse occurrences related to medications on the market are not reported. It is consequently particularly difficult to identify drug safety risks in individuals with complicated disorders and several comorbidities. Tools of ever-greater sophistication have been created throughout many years to benefit humanity. In many ways, digital computers are exactly like any other tool. They are able to carry out the similar numerical and symbolic operations that a regular person can perform, but quicker and with more accuracy. The previous several years have seen a major growth in the availability of healthcare data, and this trend is expected to continue in the near future due to widespread marketing of digital tools that collect data obtained from patients. The opportunity to use artificial intelligence (AI) approaches to enhance medication safety evaluation is presented by the vast volumes of electronic data. Information extraction collects pertinent insights from accessible, mostly unstructured sources by utilizing text mining and natural language processing (NLP) tools. Lots of application of artificial

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

intelligence areas; Artificial intelligence in ADR and ADE, Artificial Intelligence in process safety report, Artificial intelligence in drug- drug interaction, Artificial intelligence in identify patient, Artificial intelligence in predicting drug side effect etc.

Keywords: *Pharmacovigilance, Artificial intelligence, Machine learning, Adverse Drug Reaction, Adverse Drug Events, Natural Language Processing.*

Introduction

Pharmacovigilance has a critical role in promoting patient safety for both recent medications that have been introduced and those that are well-known brands. In the context of clinical trials, pharmaceutical operations are tightly regulated; nonetheless, post-marketing adverse event Reporting is not properly enforced or put into practice. As a result, it is estimated that 90% of adverse occurrences related to medications on the market are not reported. It is consequently particularly difficult to identify drug safety risks in individuals with complicated disorders and several comorbidities. Patients undergoing dialysis who have end-stage renal disease and frequently other comorbidities including diabetes, Patients with diabetes, hypertension, and cardiovascular disease present substantial treatment problems. Patients get a variety of pharmacological drugs in addition to dialysis through sophisticated medical equipment (such as a home cycler for peritoneal dialysis). The actual dialysis (such as solutions for peritoneal dialysis). Diabetes, hypertension, and cardiovascular disease present substantial therapy hurdles because many of the pharmaceuticals used to treat these individuals were developed in populations without these comorbidities. Patients get a variety of pharmaceutical agents as part of their dialysis regimen, such as peritoneal dialysis solutions, in addition to utilizing sophisticated medical equipment, such as a home cycler for peritoneal dialysis. Several of the medications used to treat these people were created in populations who did not have these problems, so a thorough understanding of potential issues and limitations in the dialysis community is deficient. The nephrology community should comprehend the meaning of pharmacovigilance, which is the pharmacologic science associated with the identification, evaluation, comprehension, and prevention of side effects from

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

medications, especially those that are both short-and long-term. Global regulatory bodies, pharmaceutical firms, healthcare providers, and patients themselves all have distinct and important responsibilities to play in this process. The definitions of adverse event reporting procedures and pharmacovigilance science are provided in this review. Demonstrates the new paths that pharmacovigilance has taken and gives HCPs who are in charge of dialysis patient's insight into the significant role that they play in assisting in the safety profile of a medication to continuously improve patient safety [1].

The pharmaceutical science that deals with the identification, evaluation, comprehension, and avoidance of side effects particularly both short- and long-term of medications is known as Pharmacovigilance. Pharmacovigilance is crucial in assisting in the monitoring of drug safety, even if it is not widely recognized by the general public. Guarantee patient safety for both recently approved medications and those with a long history of use. Each of the following parties is involved in pharmacovigilance in a different and crucial way: consumers, pharmaceutical corporations, health care professionals (HCPs), and international regulatory organisations. The science of pharmacovigilance and the adverse event reporting process are defined in this paper, with special attention to the reporting problems. Complex illnesses such end-stage renal disease (ESRD). This review gives HCPs insight into the new paths that pharmaceutical covigilance has followed. Into the significant part they play in assisting in the shaping of the comprehension of a medication's safety profile in order to consistently improve patient safety. Individuals with end-stage renal disease (ESRD) and chronic kidney disease (CKD) face numerous obstacles and complicated treatment plans.

A range of pharmacological therapies are necessary in addition to those required to manage renal insufficiency itself when there are several comorbidities, such as diabetes, hypertension, and cardiovascular disease. The influence of chronic renal replacement therapy, which has its own set of side effects but where pharmacological effects may either be the cause of an emerging issue or interact with it, further complicates this already complex scenario. Numerous medications used to treat CKD/ESRD patients were created in populations without substantial comorbidities, with normal renal function, and without

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

the added difficulty of comprehending the changed pharmacokinetic effects as a result of fluid balance, volume of distribution, and reduced renal excretion. The effects of a medication safety concern in an end-stage [2].

Tools of ever-greater sophistication have been created throughout many years to benefit humanity. In many ways, digital computers are exactly like any other tool. They are able to carry out the similar numerical and symbolic operations that a regular person can perform, but quicker and with more accuracy. Whether we can create a computer (or computer programmes) that is capable of thought is a more exciting concept. According to Penrose (1989), the majority of us are content with machines that make physical tasks like digging a whole or driving down a motorway easier or faster for us. We also take great pleasure in using machines to perform physical tasks like flying that would be impossible without them. But the notion of a computer that is capable of thinking for humans represents a significant advancement in human goals and begs a number of moral and philosophical issues. The goal of artificial intelligence (AI) research is to develop the concepts of intelligence and construct a computer of this kind.

The science of teaching a machine to mimic human mental functions is known as artificial intelligence. The pinnacle of accomplishment in this domain would be building a device that is capable of simulating or surpassing human mental functions, such as perception, understanding, reasoning, creativity, and emotion. Even though we are still far from reaching this goal, there have been some notable achievements [3].

More importantly, perhaps, in attaining these meagre results, artificial intelligence research has led to the creation of a family of incredibly helpful computing instruments. These tools have made it possible to solve many issues that were previously thought to be too tough as well as to solve many other issues more successfully. This is what, from a practical standpoint, makes them intriguing and valuable in and of themselves.

These general categories can be used to classify AI tools:

- Knowledge-based systems (KBSs), which are verbal and symbolic explicit models;
- Computational intelligence (CI), which includes hybridization and implicit modelling using numerical approaches [4].

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

Techniques including rule-based, model-based, frame-based, and case-based reasoning fall within the first category. Since the information is clearly represented by words and symbols, it is readable and intelligible to humans. While there is no denying the success of symbolic techniques in their own fields, their applicability is inherently restricted to clearly modelled scenarios. Symbolic models are often bad at handling the unknown, while certain systems let the model grow with experience. A partial solution to these challenges is provided by computational intelligence, which allows the computer to create its own model from observations and experience. This is where the Instead of being expressed verbally, knowledge is represented by numbers that are modified as the accuracy of the system increases. Neural networks, evolutionary algorithms, and other optimization approaches fall under this area, along with fuzzy logic and other methods for dealing with uncertainty. It's difficult to pinpoint the exact start of artificial intelligence research. George Boole (1815–1864) produced a wealth of concepts about the mathematical study of mental processes. And a few of his concepts are still used in the field of artificial intelligence today. The aforementioned criteria, however, seems to disqualify him as the creator of artificial intelligence because he lacked a computer. The origins of artificial intelligence (AI) are a subject of debate among historians, much as there is disagreement over who constructed the first programmed computer on both sides of the Atlantic. In order to ascertain whether a computer exhibits intelligence, British historians use Alan Turing's 1950 paper, which contained the infamous Turing test (Turing, 1950). The Dartmouth meeting in 1956, which was specifically promoted as a study of artificial intelligence and is thought to be the first instance of the term being published, is what American historians like to cite. A field evaluation is appropriate as that historic event's golden jubilee draws near [3].

Artificial Intelligence with Pharmacovigellence

The previous several years have seen a major growth in the availability of healthcare data, and this trend is expected to continue in the near future due to widespread marketing of digital tools that collect data obtained from patients. The opportunity to use artificial

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

intelligence (AI) approaches to enhance medication safety evaluation is presented by the vast volumes of electronic data. Information extraction collects pertinent insights from accessible, mostly unstructured sources by utilizing text mining and natural language processing (NLP) tools.

Has been becoming more significant in the clinical research field. Text mining and natural language processing techniques can be highly helpful in pharmacovigilance to obtain data about adverse medication drug safety by providing researchers and physicians with access to adverse drug reactions (ADRs) and drug-drug interactions from a variety of textual sources [5]. In fact, efforts are already being made by both public and private organisations to create AI technologies that will enable the processing of ADRs automatically. In pharmacovigilance, artificial intelligence and machine learning may also be helpful for the following purposes:

1) The automatic completion of case report entry and processing activities,
2) The clusters of adverse events that serve as symptoms for syndromes,
3) Conducting pharmacoepidemiological studies,
4) Connecting data by conducting probabilistic matching within datasets, and
5) Utilizing specific models to predict and prevent adverse events based on real-world data [6].

Machine learning

There are four categories of machine learning techniques: (a) Reinforcement Learning; (b) Semi-Supervised Learning; (c) Unsupervised Learning; and (d) Supervised Learning. Given that each machine learning technique can be applied to Real Time Engineering applications, we have provided a brief overview of each of the four types of ML approaches as follows:.

1) Reinforcement learning (RL): Using an environment-driven methodology, RL enables software agents and machines to automatically determine the best course of action to improve efficiency in a given situation. Reward or penalty is the foundation of reinforcement learning (RL), and

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

this method aims to maximize reward and minimize penalty by employing insights gleaned from the environment to guide decision-making. With the use of trained artificial intelligence models, RL can be used to automate processes such as supply chain logistics, manufacturing, robotics, autonomous task driving, and more. It can also be used to optimize operations [7].

2) Semi- supervised learning: This approach is semi-supervised because it can be applied to both labeled and unlabeled data. It falls between the "with supervision" and "without supervision" learning approaches and is regarded as a hybrid approach. The large amounts of unlabeled data and the uncommon amounts of labeled data that are available in a variety of contexts make the semi-supervised approach valuable in real-time [7]. When compared to predictions based solely on labeled data, the semi-supervised approach accomplishes the goal of prediction more successfully. Machine translation, fraud detection, text classification, data labeling, etc. are a few of the typical duties [8].

3) Unsupervised learning: Unsupervised analysis involves taking datasets that contain unlabeled data and analyzing them using a data-driven process with little to no human interaction. Unsupervised approaches are commonly employed in data exploration, result grouping, structure and trend identification, and general feature extraction. The most common unsupervised tasks are anomaly detection, association rule discovery, dimensionality reduction, feature learning, density estimation, and clustering [9].

4) Supervised learning: the process of creating a function to learn to map input to output in the supervised approach [8]. Using labeled training data and a collection of training examples, a function is inferred. Supervised learning is a task-driven approach that is started when specific inputs are able to achieve a range of objectives. Regression and classification are the two supervised learning tasks that are most used [10].

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

Working process for artificial intelligence:



Fig 1(AI working)

Application of artificial intelligence in pharmacovigellence

Although the writers' definitions of machine learning differed from article to article, they generally involved using algorithms or pattern recognition to carry out a given task. Numerous papers also recognized that the application of machine learning can result in the creation of intelligent automated systems that can be utilized for process optimization. how artificial intelligence is used in pharmacovigilance and patient safety The most popular uses of AI in this field included the recognition or description of ADEs and ADRs, the categorization of free text in safety reports, the extraction of drug-drug

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

interactions as well as the identification of groups of people who are more susceptible to drug toxicity [11].

1. Artificial intelligence in ADR and ADE

ADEs and ADRs can be found using machine learning, together with managing signal detection and safety surveillance. The automated classification of first-person complaints of ADRs in social media is one use of machine learning. Micro-blog postings (often known as "tweets") that detailed specific patient experiences, they used Twitter to obtain evidence regarding adverse drug reactions. Using keywords associated with selective serotonin reuptake inhibitors (SSRIs) and cognitive enhancers, they manually analyzed 1548 tweets. They demonstrated the value of using machine learning techniques to post-marketing by successfully identifying first-hand experiences in the tweets using a variety of supervised machine learning models. Social media pharmacovigilance initiatives. Several other articles have discussed the use of machine learning in social media, and the majority of them have found that there are several benefits to this approach, such as the capacity to identify adverse drug reactions (ADRs) that medical professionals might miss, the speed at which large amounts of data can be processed and analyzed, and the wealth of personal information that is available in social media posts related to ADRs [12].

Excess "noise" in the data and the casual or erratic language that is frequently employed in social media messages are among the drawbacks. Furthermore, processing in social media posts and discovered that, in contrast to higher levels of social media processing that employ natural language processing (NLP), there is a tradeoff between the amounts of manual screening required in lower levels of social media processing and its potential to miss adverse events. These chances may arise during pre-marketing to post-marketing safety reviews, among other stages of the medication development process. As patients continue to come with different disease conditions, drugs, and adverse drug reactions (ADRs), the automation inherent in machine learning approaches is becoming more and more valuable.

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

By comparing rule-based searches and semi-supervised machine learning against a reference standard, several organizations, including Connecticut Children's Medical Center, have effectively used machine learning to expedite the usage of adverse event reports.

Machine learning can be explicitly used to classify ADRs in addition to being used to detect ADRs. It used a variety of algorithms to grade the severity of patient cases according to their accuracy, recall, and precision. Additionally, artificial intelligence can be very beneficial in some illness situations, including diabetes. Early detection of hypoglycemia incidents from secure data inputs has been made possible by Hypo Detect, an NLP system that displays blood glucose measurements in a graphical format and uses an algorithm to analyze the measurements for hypoglycemic events. This allows for the prompt initiation of treatment. When a patient has an illness like diabetes, early symptom detection is essential to their safety. Systems like Hypo Detect can enhance patient outcomes and safety initiatives. Similarly, underreporting safety events has been a problem in recent years and potentially jeopardize patient safety. The approach may be helpful in starting quality control procedures early on and reporting possible negative events as soon as possible. Since each ADR must be thoroughly evaluated within a certain amount of time, this might be extremely important to patient safety [13].

The capacity of machine learning to evaluate vast amounts of data and obtain knowledge about the negative effects of treatments, which may then be utilized to enhance pharmacovigilance systems, was a recurring subject in several of the publications. Using propensity scores to introduce a novel automated signal identification technique for pharmacovigilance systems is one creative way to address issue. Naturally, one of the problems with these methods is that they produce a sufficient amount of signals with the fewest potential spurious correlations for professionals to analyze further. Using deep learning neural networks or prediction models to model the ADR link between a medicine and symptoms is another innovative method. In particular, E-Synthesis is a Bayesian framework for safety evaluations that gathers information to produce the Bayesian likelihood that a medication will result in an adverse drug reaction. Analyzing the safety

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

profile of drugs and conducting pharmacovigilance might benefit greatly from this connection. Using deep learning neural networks or prediction models to model the ADR link between a medicine and symptoms is another innovative method. In particular, E-Synthesis is a Bayesian framework for safety evaluations that gathers information to produce the Bayesian likelihood that a medication will result in an adverse drug reaction. Analyzing the safety profile of drugs and conducting pharmacovigilance might benefit greatly from this connection [12].

2. **Artificial Intelligence in process safety report:**

   Assessing the ability of natural language processing (NLP) to categorize unstructured free text in patient safety incident reports is another way that machine learning is being used in pharmacovigilance. NLP can serve as a safety net by identifying situations that result in severe harm or death, testing of the system's ability to classify free text inside patient safety event reports autonomously to evaluate the severity of harm outcomes. It is not a flawless approach, though, and it cannot yet completely replace manual evaluation. It's also challenging to finish this process because medical tests are technical in nature [14]. Numerous studies examined how machine learning might be used to filter patient safety reports from sources like electronic health records text mining and machine learning algorithms are helpful techniques for sorting through and evaluating big, semi-structured, or unstructured data sets of near-miss and adverse event reports gathered from passive surveillance reporting systems. In a more focused manner, deep learning model to detect allergic responses in the free-text narrative of hospital safety reports and assessed its generalizability using several data sets. According to the study, the model has the potential to enhance allergy care by allowing for real-time event tracking for medical errors and system enhancement. In the end, machine learning can be applied in a variety of contexts to meet the needs of pharmacovigilance, such as post-marketing surveillance of adverse drug reactions in the pharmaceutical industry and identifying keywords in patient safety reports that may need to be addressed to prevent harm at clinical sites [15].

3. **Artificial intelligence in drug- drug interaction:**

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

Drug-drug interactions can be retrieved or their effects predicted using artificial intelligence. For the successful extraction of drug–drug interactions, combined machine learning approaches with both feature-based and kernel-based methodologies. A technique for automatically identifying drug-drug interactions was employed enhance drug safety monitoring in a hospital environment. Using laboratory test results and treatment data, they developed an effective machine learning model that could identify patients who might have experienced an adverse drug event (ADE) associated with a drug-drug interaction. Because machine learning algorithms may learn from a small number of drug-drug interaction combinations to anticipate many possible drug-drug interactions, they can be very helpful in pharmacovigilance [16].

4. Artificial intelligence in identify patient:

ADR-prone groups can be identified using machine learning, which can also be used to inform individualized treatment. Using a machine learning adaption of propensity score matching, Chandak and Tatonetti developed "Award: Analyzing Women At Risk for Experiencing Drug toxicity," a machine learning system that predicts with high precision the risks of adverse drug effects specific to a certain sex. Additionally, more specific patients can be identified with machine learning approaches, such as those who are at risk of fluoropyrimidine toxicity as a result of DPD deficiency. Researchers trained toxicity patterns using machine learning models, and then used those models to estimate the number of patients with DPD-related toxicity. They discovered that while the model may have some over fitting, it has potential for usage in the future. These methods are a great place to start, even though there is still room for improvement in the use of machine learning to identify patients who are at high risk of adverse drug reactions [17].

5. Artificial intelligence in predicting drug side effect:

Machine learning has been used to anticipate pharmacological side effects in addition to its application in identifying patients who are at high risk of developing adverse drug

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

reactions. With an emphasis on post-marketing drug surveillance, Mower et al. showed how downstream machine learning techniques can improve the efficacy of spontaneous reporting system techniques by using knowledge obtained from literature. Because spontaneous reporting methods frequently involve bias and underreporting, which can limit the availability of data, this can be especially helpful in forecasting pharmacological adverse effects. A tumor-biomarker knowledge network, researchers predicted possible side effects and ADRs and found that this strategy is helpful for potential biomarker-based ADR identification. Future applications that might call for mechanism-based ADR research may find value in the model [18].

6. **Artificial intelligence in stimulating clinical trials:**

Machine learning combined with real-world data to assess severe adverse events and replicate colorectal cancer clinical trials. The risk ratios derived from the trials and the risk ratios of significant adverse events determined from simulations comparing two treatment arms were remarkably similar, demonstrating the potential value of machine learning and real-world data in modeling clinical trials [19].

7. **Artificial intelligence to Integrate Prediction Uncertainties:**

Prediction uncertainty in patient safety can potentially be integrated with artificial intelligence. The uncertainty of computer-aided diagnosis based on deep learning for patient safety was measured. The work's foundation is the idea that models trained for case diagnosis frequently lack the ability to recognize when a case is too unclear to produce an output. According to the study, deep learning modeling of prediction uncertainty can yield more consistent outcomes that can support safety initiatives [20].

Future Aspects:

Future studies on the application of artificial intelligence in pharmacovigilance have a lot of potential because it is being used more and more in a variety of fields, not just healthcare. To test whether the artificial intelligence technology can respond accurately and efficiently, future research may use databases with more complex input

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

text or more "noise." The majority of the articles utilized Twitter as their database when it came to social media sites. The growing interest in the use of social media for pharmacovigilance in recent years makes other social media platforms, like health care social networks, worth evaluating. Finally, more research assessing the potential cost savings in healthcare that automated machine learning techniques can bring about may prove helpful [18]. Artificial intelligence and machine learning may also be useful in pharmacovigilance for 1) the automatic execution of tasks associated with case report entry and processing, 2) the identification of clusters of adverse events representing symptoms of syndromes, 3) the conduction of pharmacoepidemiological studies, 4) data linkage, through the conduction of probabilistic matching within datasets and 5) the prediction and prevention of adverse events through specific models using real-world data.

Conclusion:

Artificial intelligence is actively being used in pharmacovigilance and patient safety to gather information on ADRs and ADEs, to perform surveillance and signal detection, to process ICSRs, to process patient safety event reports and clinical narratives, to extract drug–drug interactions and predict the effects of drug–drug interactions, to identify populations at high risk for experiencing ADRs and guide personalized care, to predict drug side effects, to simulate clinical trials, and to integrate prediction uncertainties into diagnostic classifiers to increase patient safety. There is potential for artificial intelligence to be used in pharmacovigilance and patient safety in more ways than were identified in this review in the coming years as people gain more exposure to artificial intelligence methods. The growth of this field may be limited by challenges related to the lack of validated, established uses of artificial intelligence in real-life safety settings.

References:

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

1. Geneva WH. The importance of pharmacovigilance, safety monitoring of medicinal products. Technical report series 2002; 2002.
2. Teach GH. Serum and urine biomarkers of kidney disease: A pathophysiological perspective. Nephrology. 2010 Sep; 15(6):609-16.
3. Nowostawski M, Poli R. Parallel genetic algorithm taxonomy. In1999 Third International Conference on Knowledge-Based Intelligent Information Engineering Systems. Proceedings (Cat. No. 99TH8410) 1999 Aug 31 (pp. 88-92).
4. S. Mukkamala and A. H. Sung, A comparative study of techniques for intrusion detection, In Proceedings of 15th IEEE International Conference on Tools with Artificial Intelligence, pages 570– 577. IEEE Press, 3-5 Nov. 2003.
5. Wong A, Plasek JM, Montecalvo SP, Zhou L. Natural language processing and its implications for the future of medication safety: a narrative review of recent advances and challenges. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2018 Aug; 38(8):822-41.
6. Basile AO, Yahi A, Tatonetti NP. Artificial intelligence for drug toxicity and safety. Trends in pharmacological sciences. 2019 Sep 1; 40(9):624-35.
7. Jhaveri RH, Ramani SV, Srivastava G, Gadekallu TR, Aggarwal V. Fault-resilience for bandwidth management in industrial software-defined networks. IEEE Transactions on Network Science and Engineering. 2021 Aug 12; 8(4):3129-39.
8. Sarker IH, Kayes AS, Badsha S, Alqahtani H, Watters P, Ng A. Cybersecurity data science: an overview from machine learning perspective. Journal of Big data. 2020 Dec; 7:1-29.
9. J. Han, J. Pei, and M. Kamber, Data Mining: Concepts and Techniques, Elsevier, Amsterdam, 2011.
10. I.H.Sarker, “Deepcybersecurity: acomprehensiveoverview from neural network and deep learning perspective,” SN Computer Science, vol. 2, no. 3, 154 pages, 2021.
11. Negi K, Pavuri A, Patel L, Jain C. A novel method for drug-adverse event extraction using machine learning. Informatics in Medicine Unlocked. 2019 Jan 1; 17:100190.

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

12. Alvaro N, Conway M, Doan S, Lofi C, Overington J, Collier N. Crowdsourcing Twitter annotations to identify first-hand experiences of prescription drug use. Journal of biomedical informatics. 2015 Dec 1; 58:280-7.
13. Cocos A, Fiks AG, Masino AJ. Deep learning for pharmacovigilance: recurrent neural network architectures for labeling adverse drug reactions in Twitter posts. Journal of the American Medical Informatics Association. 2017 Jul 1; 24(4):813-21.
14. Evans HP, Anastasia A, Edwards A, Hebert P, Make ham M, Luz S, Sheikh A, Donaldson L, Carson-Stevens A. Automated classification of primary care patient safety incident report content and severity using supervised machine learning (ML) approaches. Health informatics journal. 2020 Dec; 26(4):3123-39.
15. Yang J, Wang L, Padre NA, Wicker PG, Mancini CM, Blumenthal KG, Zhou L. Development and validation of a deep learning model for detection of allergic reactions using safety event reports across hospitals. JAMA Network Open. 2020 Nov 2; 3(11):e2022836-.
16. Dewily P, Stock M, De Beats B. Cold-start problems in data-driven prediction of drug–drug interaction effects. Pharmaceuticals. 2021 May 2; 14(5):429.
17. Correia Pinheiro L, Durand J, Dogné JM. An application of machine learning in pharmacovigilance: estimating likely patient genotype from phenotypical manifestations of fluoropyrimidine toxicity. Clinical Pharmacology & Therapeutics. 2020 Apr; 107(4):944-7.
18. Wang M, Ma X, Si J, Tang H, Wang H, Li T, Ouyang W, Gong L, Tang Y, He X, Huang W. Adverse drug reaction discovery using a tumor-biomarker knowledge graph. Frontiers in genetics. 2021 Jan 12; 11:625659.
19. Chen Z, Zhang H, George T, Prosper M, Goo Y, Braithwaite D, Henchman E, Light J, Bain J. Abstract PO-071: simulation of colorectal cancer clinical trials using real-world data and machine learning. Clinical Cancer Research. 2021 Mar 1; 27(5_Supplement): PO-071.
20. Laves MH, Idler S, Ortmaier T, and Kahrs LA. Quantifying the uncertainty of deep learning-based computer-aided diagnosis for patient safety. Current Directions in Biomedical Engineering. 2019 Sep 1; 5(1):223-6.

ISSN PRINT 2319 1775 Online 2320 7876

 UGC CARE Listed (Group -I) Journal Volume 11, Iss 10, 2022

21. Montani S., Magni P., Bellazzi R., Larizza C., Roudsari A.V. and Carson E.R., "Integrating model-based decision support in a multi-modal reasoning system for managing type 1 diabetic patients", Artificial Intelligence in Medicine 29 (2003) 131–151.
22. Bruninghaus S. and Ashley K.D., Combining casebased and model-based reasoning for predicting the outcome of legal cases, in: Lecture Notes in Artificial Intelligence, vol. 2689, Springer-Verlag, Berlin/New York, 2003, pp. 65–79.
23. Koning K., Bredeweg B., Breuker J. and Wielinga B., "Model-based reasoning about learner behaviour", Artificial Intelligence 117 (2000) 173–229
24. Xing H., Huang S.H. and Shi J., "Rapid development of knowledge-based systems via integrated knowledge acquisition", Artificial Intelligence for Engineering Design Analysis and Manufacturing 17 (2003) 221– 234
25. Minton S., Carbonell J.G., Knoblock C.A., Kuokka D.R., Etzioni O. and Gil Y., "Explanation-based learning: a problem-solving perspective", Artificial Intelligence 40 (1989) 63–118.